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Summary
Objectives: Glucosamine (GlcN), a natural amino monosaccharide, is a constituent of glycosaminoglycans (GAGs) found in hyaline cartilage.
GlcN salts constitute a new class of nutraceutical components with putative chondroprotective activity, which may target chondrocytes as well
as chondroprogenitors cells, such as mesenchymal stem cells (MSCs), during cartilage turnover and repair. In the present study, we examined
the effects of GlcN on chondrogenesis of human MSCs (hMSCs) and the phenotype of normal and osteoarthritic human articular chondro-
cytes, using an in vitro pellet culture model maintained in a deﬁned medium.
Methods: hMSCs and normal and osteoarthritic human chondrocytes grown as pellet cultures, stimulated or not with interleukin-1b (IL-1b),
were treated with varying doses of GlcN. Expression of cartilage matrix genes and cartilage degrading enzymes was determined by semiquan-
titative and quantitative real-time reverse transcription polymerase chain reaction (RT-PCR), and by histological staining of cartilage markers,
as well as sulfated GAG (sGAG) analysis and Western blotting.
Results: Chondrocytes grown in the presence of serum for 11 days showed decreased expression of the cartilage matrix genes, collagen type
II (collagen II) and aggrecan, as early as day 3, which was reversed with GlcN treatment by day 11. Both hMSCs and chondrocytes grown as
pellet cultures in deﬁned medium and treated with 100 mM GlcN exhibited enhanced expression of collagen II and aggrecan as well as
increased content of sGAG, when compared to control untreated pellets. However, high doses of GlcN (10e20 mM) were inhibitory. GlcN
treatment partially blocked IL-1b mediated downregulation of collagen II and aggrecan expression and inhibited expression of the matrix
degrading enzyme, matrix metalloproteinase 13 (MMP-13), in both chondrocytes and hMSCs undergoing chondrogenesis.
Conclusions: These observations suggest that GlcN treatment enhances hMSC chondrogenesis and maintains cartilage matrix gene expres-
sion in chondrocytes, which may account for some of the reported chondroprotective properties of GlcN on cartilage.
ª 2007 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.





Articular cartilage, located at the end of long bones, con-
sists of chondrocytes embedded in a hyaline cartilaginous
extracellular matrix (ECM). The major components of the ar-
ticular cartilage ECM are collagen type II (collagen II) and
proteoglycans, and the organization and the homeostasis
of the tissue is maintained via a balance of anabolic and
catabolic functions. Osteoarthritis (OA) is a degenerative
joint disease of the articular cartilage associated with multi-
ple factors, genetic, metabolic, biochemical and biome-
chanical, that act to disturb the equilibrium of anabolic
and catabolic events, resulting in the depletion of collagens
and proteoglycans due in part to accelerated turnover and
inadequate repair1,2. In addition, local inﬂammatory activity
is a well-known component of OA3. Articular cartilage is an
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through the surrounding synovium and subchondral bone.
Interleukin-1b (IL-1b), a pro-inﬂammatory cytokine released
by synovial ﬁbroblasts, is well known to increase locally
during the osteoarthritic process4. IL-1b has been shown
to directly depress chondrocyte synthesis of aggrecan and
collagen5e7. In addition, IL-1b activates a large cascade
of mediators, such as matrix metalloproteinases (MMPs),
that play an active role in ECM degradation, leading to car-
tilage damage8.
Current pharmacological treatments of arthritis are limited
to analgesics such as oral nonsteroidal anti-inﬂammatory
drugs (e.g., ibuprofen), injectable intra-articular corticoste-
roids (betametazone) and hyaluronic acid, which control
disease symptoms and provide pain relief but do not affect
the progression of the disease. Glucosamine (GlcN) is an
aminomonosaccharide found naturally in connective tissues
and is a chemical constituent of glycosaminoglycans
(GAGs), building blocks of the large aggregating proteogly-
cans of the cartilage ECM9,10. GlcN has been touted for
more than two decades as an effective nutraceutical for the
purpose of chondroprotection. Several clinical trials that
explored the potential of GlcN and another amino6
647Osteoarthritis and Cartilage Vol. 15, No. 6monosaccharide, chondroitin sulfate, in the treatment of OA
have been recently reviewed, and some efﬁcacy of GlcN in
preventing joint space loss and relieving pain is sugges-
ted11e14. In human patients, administration of 1500 mg
GlcN/day for 3 years prevented joint space loss and relieved
symptoms when compared to placebo, suggesting that GlcN
possesses some anti-inﬂammatory activity that can alter dis-
ease progression15. More recently, a GlcN/chondroitin arthri-
tis intervention trial (GAIT) at 16 sites across the United
States showed that participants with moderate to severe
pain experienced signiﬁcant pain relief with the combined
supplements16. In vitro, GlcN treatment of human OA chon-
drocytes pretreated with IL-1b resulted in reduced activation
of cartilage catabolic mediators, such as synthesis of nitric
oxide (NO) and prostaglandin E2, and enhanced aggrecan
protein levels17e19, suggesting that GlcN may act by control-
ling inﬂammatory mediators and stimulating proteoglycan
synthesis in response to cartilage damage.
Articular cartilage is known for its poor capacity for self-
repair, likely associated with the absence of blood supply,
low mobility and a limited number of progenitor cells. Adult
progenitor cells, also known as mesenchymal stem cells
(MSCs), have been isolated from multiple human adult
tissues including bone marrow, bone, muscle, tendon and
adipose tissues. These cells have the capacity to self-
renew for a limited number of population doublings and to
exhibit the potential for multilineage differentiation, including
chondrogenesis. Interestingly, culture expanded human OA
chondrocytes grown as high-density pellet cultures in
deﬁned medium containing ascorbate and treated with
dexamethasone (DEX) and transforming growth factor-
b (TGF-b), formed cartilage with no signs of bone20. These
ﬁndings suggest that diseased chondrocytes are able to re-
vert to their normal differentiated phenotype. In addition,
MSCs were recently identiﬁed in human cartilage and their
frequency was increased in OA cartilage21. Taken together,
these observations suggest that the activity of these cells is
important in the progression of OA and other degenerative
joint diseases. We postulate that GlcN may act by altering
both chondrocyte and adult mesenchymal progenitor cell
function during cartilage turnover and repair.
To test this hypothesis, we have examined the effects of
GlcN on human OA articular chondrocytes, activated with
IL-1b. In addition, we have investigated the effect of GlcN
on the differentiation characteristics of multipotential, hu-
man MSCs (hMSCs). These cells can differentiate into
chondrogenic phenotype, when cultured as high-density
cell pellets in deﬁned medium supplemented with DEX
and TGF-b. We report here that GlcN treatment enhanced
chondrogenic phenotype of hMSCs and the chondrogenic
phenotype of OA chondrocytes, as shown by upregulation
of the expression of cartilage matrix components, collagen
II and aggrecan, and increased the levels of sulfated GAG
(sGAG). GlcN treatment also blocked IL-1b-induced MMP-
13 expression in both normal and OA chondrocytes, and
enhanced aggrecan levels in OA chondrocytes following
IL-1b challenge. These results strongly suggest that GlcN
enhances chondrogenesis of hMSCs and maintains the
chondrogenic phenotype of normal and OA chondrocytes.
Materials and methods
MATERIALS
DEX and GlcN hydrochloride (GlcN-HCl) were purchased
from Sigma (Sigma, St. Louis, MO) and were dissolved in
water as 1 mM and 100 mM stock solutions, respectively.Recombinant human TGF-b3 was from R&D systems (Min-
neapolis, MN) and dissolved in 4 mM HCl containing 0.1%
bovine serum albumin (BSA) as a 2 mg/ml stock solution.
IL-1b (R&D systems, Minneapolis, MN) was dissolved as
a 5 mg/ml stock solution in phosphate buffer saline (PBS)
containing 0.1% BSA.
INDUCTION OF CHONDROGENESIS IN hMSCs
A multipotential hMSC cell line previously established in
our laboratory was used in this study22e24. The cell line
was derived from human adult trabecular bone and stably
transduced with human papilloma virus (HPV) oncoproteins
E6/E7. hMSCs were maintained as monolayer cultures in
high glucose Dulbecco’s Modiﬁed Eagle’s Medium (DMEM)
(Biowhittaker, Walkersville, MD), containing L-glutamine,
and supplemented with 10% of speciﬁc lots of fetal bovine
serum (FBS) (Atlanta Biological, Atlanta, GA) and antibioti-
ceantimycotic solutions (10,000 U Penicillin, 10,000 mg
Streptomycin, 25 mg Amphotericin B, Gibco-Invitrogen,
Carlsbad, CA). To induce chondrogenesis, hMSCs were
cultured as high-density cell pellets formed by spinning
down 1.5 106 cells in a 50 ml conical tube, and main-
tained in chondrogenic medium consisting of serum-free
DMEM containing insulinetransferrineselenious acid mix
(ITS) (BD Biosciences, Bedford, MA), 100 mg/ml sodium
pyruvate, 40 mg/ml L-proline, 50 mg/ml L-ascorbic acid
2-phosphate, in the presence of 100 nM DEX and 10 ng/ml
TGF-b3. After 3 days of culture to allow cell aggregation, the
pellets were treated with the indicated concentrations of
GlcN. Control cultures consisted of cells incubated in chon-
drogenic medium (with DEX and TGF-b3). In other experi-
ments, cultures were treated at day 11 with 5 ng/ml IL-1b
for 24 h, washed and then incubated for an additional 10
days in chondrogenic medium in the presence or absence
of GlcN at the indicated concentrations. The cultures
were processed for sGAG assays, RNA isolation and
reverse transcription polymerase chain reaction (RT-PCR)
analysis, as well as histochemical and immunohistochemical
analyses after ﬁxation in 4% paraformaldehyde.
ISOLATION AND CULTURE OF CHONDROCYTES
Normal human articular cartilage was purchased from
National Disease Research Interchange (NDRI) (Philadel-
phia, PA) and OA articular cartilage was obtained from pa-
tients undergoing knee arthroplasty at George Washington
University according to an IRB approved protocol. To iso-
late normal and OA chondrocytes, cartilage was shaved
off the femoral condyle and the tibial plateau, washed three
times with PBS and digested with 0.1% Trypsineethylene
diamine tetraacetic acid (EDTA) in serum-free culture me-
dium for 1 h at 37C under agitation. After washing in
PBS, the cartilage pieces were minced, and then digested
with collagenase 2 (Sigma) at 50 mg/ml in serum-free me-
dium overnight at 37C under agitation. The chondrocyte
suspension was ﬁltered through a 40 mm cell strainer,
washed with PBS, and plated at 1.5 105 cells/cm2 in
DMEM containing 10% FBS and antibioticeantimycotic so-
lutions. Cells were allowed to adhere, spread and proliferate
for 7e10 days. Normal and OA chondrocytes were used for
experiments between P1 and P2.
Primarychondrocyteswere culturedaseithermonolayeror
high-density pellets and maintained in either control medium
(high glucose DMEM with 10% FBS) or in deﬁned medium
(high glucose DMEM, ITS, sodium pyruvate, L-proline and
L-ascorbic acid 2-phosphate). For pellet cultures, cells were
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subjected to the following treatments: (1) treatment with
5 ng/ml IL-1b for 24 h at either day 1 or day 11; and (2) treat-
ment with GlcN for an additional 10 days (after IL-1b treat-
ment at day 11) or 20 days (after IL-1b treatment on day
1). Monolayer cultures were grown in control medium (high
glucose DMEM with 10% FBS) for 24 h, and then treated
with GlcN for 3, 7 and 11 days. Harvested cultures were pro-
cessed for RNA isolation followed by RT-PCR, histochemi-
cal and immunohistological analyses, as described above.
RT-PCR ANALYSIS OF GENE EXPRESSION
Total RNA was extracted from monolayer and pellet
cultures using the Trizol reagent (Invitrogen, Carlsbad,
CA). Reverse transcription was done using 0.5e1 mg RNA
and a one step RT-PCR was carried out according to the
manufacturer’s protocol (Invitrogen, Carlsbad, CA). Reverse
transcription reactions were performed at 50C for 30 min
and terminated by incubation at 94C for 2 min. PCR was
carried out for 40 cycles of ampliﬁcation, consisting of 94C
for 30 s, 55e60C for 30 s and 72C for 45 s. For real-time
RT-PCR analyses, total RNA (1e5 mg) was reverse tran-
scribed using Invitrogen’s ﬁrst strand DNA synthesis kit.
Real-time PCR reactions were carried out using 10 ng of
cDNA and Syber Green mix (Biorad Laboratories, Hercules,
CA). Reactions were carried out for 40 cycles of ampliﬁca-
tion, consisting of denaturation at 94C for 30 s, annealing
at 57e60C for 30 s and elongation at 72C for 30 s. To con-
trol for reaction speciﬁcity, PCR products were melted for
1 min, re-annealed, and then ampliﬁed for 18e20 cycles at
Tmþ 1C increment at each cycle. Quantitative analyses
were performed using BioRad iCycler software, and stan-
dard curves were generated using 10-fold serial dilutions of
cDNA with a correlation coefﬁcient of 0.9 and a PCR efﬁ-
ciency of 80%. Speciﬁc primers for aggrecan, collagen II,
MMP-13, and glyceraldehyde 3-phosphate dehydrogenase
(G3PDH) were designed based on their corresponding Gen-
Bank cDNA sequence. Primer sequences used in semiquan-
titative and real-time PCR and predicted size of the PCR
products are presented in Table I.
HISTOLOGICAL AND IMMUNOHISTOCHEMICAL ANALYSES
Pellet cultures were ﬁxed in 4% paraformaldehyde,
dehydrated using a graded series of ethanol washes, andembedded in parafﬁn. Sections of 8 mm in thickness were
stained with alcian blue. For immunohistochemical analy-
ses, sections were pre-digested with hyaluronidase (Sigma)
in 10 mM TriseHCl, pH 7.5, for 30 min at 37C, then incu-
bated overnight at room temperature with the indicated
antibodies in Tris buffered saline (TBS; pH 7.4) containing
0.1% BSA. Speciﬁc antibodies to aggrecan and collagen
II were obtained from Developmental Studies Hybridoma
Bank (Iowa City, IA). Immunostaining was detected by
using the chromogenic Streptavidin-Peroxidase Histostain
SP Kit for DAB (Zymed Laboratories, San Francisco, CA).
Cells were examined using a Leica microscope at the indi-
cated magniﬁcation.
sGAG ASSAY
Pellet cultures were digested overnight at 60C with
300 mg/ml papain (Sigma) in 20 mM sodium phosphate
buffer, pH 6.8, containing 5 mM EDTA and 2 mM dithio-
threitol (DTT). Cell lysates were cleared by centrifugation
and sGAG was determined using the Blyscan sGAG as-
say kit (Biocolor Ltd, UK) according to the manufacturer’s
procedure. Brieﬂy, cell lysates were incubated with the
dye reagent 1,9-dimethylmethylene blue (DMMB), for
30 min, and unbound dye removed by centrifugation.
Bound dye was dissociated from the sGAGedye complex
and quantiﬁed spectrophotometrically based on A656. Us-
ing chondroitin 4-sulfate as a standard, total sGAG was
determined and was expressed as a function of protein
content.
WESTERN BLOT ANALYSIS
Harvested cultures were washed with cold PBS, and
lysed in a buffer containing 0.1% NP-40, 10 mM TriseHCl,
pH 7.9, 10 mM MgCl2, 15 mM NaCl, 0.5 mM phenylmethyl
sulfonyl ﬂuoride (PMSF), and protease inhibitor cocktail
(Roche, Indianapolis, IN) to isolate cytoplasmic proteins.
Cell extracts (25e50 mg protein) were resolved by sodium
dodecyl sulfate (SDS) polyacrylamide gel electrophoresis
and transferred to nitrocellulose. After transfer, the ﬁlters
were blocked for 1 h with 2% BSAeTBSe0.1% Tween-20,
incubated with MMP-13 antibody (R&D systems, Minneap-
olis, MN) or b-actin antibody (Sigma), followed by 1-h
incubation with a horseradish peroxidase-labeled goatTable I
Primer Sequence Annealing ((C) Product size (bp)
Semiquantitative PCR primers
Aggrecan (F) 50-TGA CCA CTT TAC TCT GGG TTT TCG-30 57 350
Aggrecan (R) 50-ACA CGA TGC CTT TCA CCA CG-30
Col II (F) 50-CCG CGG TGA GCC ATG ATT CG-30 57 377 (IIA)
Col II (R) 50-CAG GCC CAG GAG GTC CTT TGG G-30 171 (IIB)
MMP-13 (F) 50-ACT TTA TGC TTC CTG ATG ACG ATG-30 57 590
MMP-13 (R) 50-TGC TGT ATT CAA ACT GTA TGG GT-30
G3PDH (F) 50-ACC ACA GTC CAT GCC ATC AC-30 59 450
G3PDH (R) 50-TCC ACC ACC CTG TTG CTG TA-30
Real-time PCR primers
Aggrecan (F) 50-CAC GAT GCC TTT CAC CAC GAC-30 57 181
Aggrecan (R) 50-TGC GGG TCA ACA GTG CCT ATC-30
Collagen IIB (F) 50-GGA AAC TTT GCT GCC CAG ATG-30 59 167
Collagen IIB (R) 50-TCA CCA GGT TCA CCA GGA TTG C-30
MMP-13 (F) 50-AAC GCC AGA CAA ATG TGA CCC-30 57 120
MMP-13 (R) 50-TCC GCA TCA ACC TGC TGA GG 30
G3PDH (F) 50-CAA GGC TGA GAA CGG GAA GC-30 57 194
G3PDH (R) 50-AGG GGG CAG AGA TGA TGA CC-30
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ences, Piscataway, NJ). Immunoreactive protein bands
were detected using a chemiluminescence detection sys-
tem (Pierce Biotechnology, Rockford, IL).
Results
LOW DOSES OF GLCN ENHANCE CHONDROGENESIS
OF hMSCs
High-density pellet cultures of hMSCs undergoing chon-
drogenesis were treated with GlcN at various concentra-
tions to test the effect on the expression of markers of
chondrogenic phenotype. Chondrogenesis was induced
for 21 days by maintaining the cultures in a chondrogenic
medium containing 100 nM DEX and 10 ng/ml of TGF-b3
in the absence or presence of 50 mMe20 mM GlcN. In initial
experiments, it was found that the addition of GlcN during
the early steps of high-density pellet formation disrupted
the integrity of the cell pellet, and resulted in lack of chon-
drogenic marker gene expression (data not shown). Conse-
quently, to assess the effect of GlcN on chondrogenesis,
GlcN treatment was started at day 4 after the cell pellet
was well formed, and was continued through day 21. To
quantify the effect of GlcN on chondrogenesis of hMSCs,
we carried out real-time RT-PCR analysis of total RNA
prepared from day 21 hMSC pellet cultures maintained in
chondrogenic medium containing DEX and TGF-b3, in the
presence or absence of 100 mM, 1 mM or 10 mM GlcN.
As shown in Fig. 1, expression of the cartilage matrix
genes, aggrecan and collagen II (II B RNA isoform) was in-
duced in control cultures maintained in chondrogenic
medium, indicating the induction of a chondrogenic pheno-
type in the hMSC cultures under these experimental
conditions. As shown in Fig. 1 (left panel), expression of
aggrecan in pellet cultures treated with 1 mM GlcN was en-
hanced by over 30% compared to control untreated pellets.
Similar upregulation of collagen II gene expression was ob-
served in the presence of 1 mM GlcN [Fig. 1(B), right panel].
However, treatment with 10 mM GlcN resulted in the inhibi-
tion of both aggrecan and collagen II gene expression
relative to untreated control. Physiological plasma GlcN
concentrations ranged from 150 mM to 300 mM, in human
adults ingesting a typical dose of GlcN supplement of
1500 mg/day (20 mg/kg in a 75 kg subject)25. These results
showed that GlcN concentrations within the range achievedphysiologically with oral dosing of GlcN enhanced cartilage
speciﬁc cartilage ECM gene expression during chondrogen-
esis of hMSCs, while higher doses were inhibitory.
We next examined by immunohistochemistry the effect of
GlcN treatment on aggrecan and collagen II protein in sec-
tions of day 21 hMCS pellet cultures maintained in chondro-
genic medium. In control cultures, cartilage phenotype was
demonstrated by immunostaining of aggrecan and collagen
II (Fig. 2). Treatment of hMSCs undergoing chondrogenesis
with 100 mM or 1 mM GlcN did not appear to affect collagen
II levels, but substantially enhanced aggrecan protein level
as shown by immunostaining (Fig. 2). Biochemical analysis
of cultures treated with 100 mM GlcN contained signiﬁcantly
higher levels of sGAG levels as compared to untreated con-
trol, while 10 mM GlcN treatment was inhibitory. However,
no signiﬁcant increase in sGAG was observed when cells
were treated with 1 mM GlcN (Fig. 3). This discrepancy be-
tween the RNA and aggrecan/sGAG levels at 1 mM GlcN
could result from the spatial heterogeneity of differentiation
under these conditions; i.e., intense aggrecan immunostain-
ing in the periphery of the pellet at a higher level than that of
the control, but reduced aggrecan immunostaining in the
center of the pellet when compared to the cultures treated
with 100 mM GlcN and control (Fig. 2). Taken together,
these results showed that GlcN concentrations within the
range achieved physiologically with oral dosing of GlcN en-
hanced production of cartilage speciﬁc matrix components
during chondrogenesis of hMSCs.
GLCN IS EFFECTIVE IN MAINTAINING CHONDROGENIC
PHENOTYPE
We next examined whether the pro-chondrogenic effect
of GlcN also applied to primary human chondrocytes. Treat-
ment of chondrocyte pellet cultures with various doses of
GlcN showed that doses ranging from 50 mM to 10 mM
GlcN enhanced or maintained collagen II and aggrecan
gene expression, but doses higher than 10 mM were inhib-
itory (data not shown). To further characterize the effect of
GlcN on the maintenance of chondrocyte differentiation
markers, we performed a time course analysis of collagen
II and aggrecan gene expression in both monolayer and
high-density pellet cultures of chondrocytes maintained in
serum-containing medium supplemented with ascorbate
and treated with 10 mM GlcN for up to 11 days. RT-PCR
analysis of monolayer cultures showed that expression ofFig. 1. Effect of GlcN on expression of cartilage matrix gene expression during chondrogenic differentiation of hMSCs. High-density pellet
cultures of hMSCs undergoing chondrogenesis in deﬁned medium supplemented with DEX and TGF-b were co-treated with various doses
of GlcN from day 11 through day 21 and total RNA was subjected to quantitative RT-PCR analysis of cartilage marker gene expression
with G3PDH as an internal control. Levels of speciﬁc gene expression (expressed as average copy number relative to that of G3PDH)
show that treatment with 100 mM and 1 mM GlcN signiﬁcantly (P 0.001) enhanced both aggrecan (left) and collagen II (right) gene expres-
sion, while treatment with 10 mM GlcN was inhibitory (P 0.05) for both genes in hMSCs undergoing chondrogenesis. The data represent the
meanSD (*P 0.05) as determined by ANOVA, of three independent experiments performed in triplicate.
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grown in the presence of DEX and TGF-b and treated in the presence of the indicated amount of GlcN were ﬁxed and sections were immu-
nostained for aggrecan and collagen II. While GlcN treatment did not appear to affect collagen II staining, aggrecan levels were increased by
100 mM GlcN and to a lower extent by 1 mM GlcN treatment.both aggrecan and collagen II (IIB mRNA isoform) was
downregulated in a time-dependent manner. In comparison,
under high-density pellet cultures conditions, untreated pri-
mary chondrocytes maintained expression of aggrecan and
collagen IIB up to day 7 and expressed higher levels of col-
lagen IIA mRNA isoform [Fig. 4(A)]. After day 7, aggrecan
and collagen IIA levels decreased while collagen IIB re-
mained unchanged. Interestingly, GlcN treatment partially
reversed the decrease in aggrecan in both monolayer and
pellet cultures and further maintained the levels of collagen
IIA mRNA in pellet cultures [Fig. 4(A)].
Immunohistochemistry of collagen II showed low levels of
staining in monolayer cultures and, in pellet cultures, in-
creased levels of collagen II were detected in sections of
GlcN-treated cultures, when compared to untreated cul-
tures. In addition, alcian blue staining of sulfated proteogly-
cans was increased in monolayer cultures treated with GlcN
when compared to untreated controls, and was maintained
at equivalent levels in pellet cultures grown in the presence
or absence of GlcN [Fig. 4(B)]. Thus, GlcN treatment main-
tained cartilage ECM marker gene expression and the
levels of matrix components in chondrocyte cultures grown
in the presence of serum in vitro.
GLCN BLOCKS IL-1b-INDUCED INHIBITION OF MATRIX
GENE EXPRESSION IN OA CHONDROCYTES
To assess the chondroprotective activity of GlcN, high-
density pellet cultures of human OA chondrocytes were
grown in deﬁned medium containing ITS, treated with 5 ng/
ml IL-1b for 24 h at day 1, then exposed to varying doses
of GlcN for additional 10 days, and cartilage marker gene ex-
pression analyzed by quantitative RT-PCR. As shown in
Fig. 5(A), treatment with IL-1b inhibited both aggrecan and
collagen II (IIB) basal gene expression. Expression of aggre-
can was signiﬁcantly enhanced by 100 mM and 1 mM GlcN
treatment post-IL-1b exposure. In contrast, GlcN treatment
alone at 100 mM enhanced collagen II (IIB) levels but pro-
vided little protection for the effect post-IL-1b treatment
[Fig. 5(A)]. However, treatment with 10 mM GlcN, either
with or without IL-1b, resulted in a signiﬁcant inhibition of ag-
grecan and collagen II gene expression relative to untreated
control [Fig. 5(A)]. Taken together, this data showed that
treatment of chondrocyte pellet cultures with 100 mM and
1 mM GlcN, post-IL-1b exposure, maintains collagen II and
stimulates aggrecan and gene expression.Biochemical analysis showed increased levels of sGAG in
cultures treated with 100 mMGlcN as compared to untreated
control, while 10 mM GlcN treatment was inhibitory. No sig-
niﬁcant change in sGAG was seen when cultures were
treated with 1 mM GlcN [Fig. 5(B)]. Aggrecan immunohisto-
chemistry and alcian blue staining of sections of OA chon-
drocyte pellet cultures showed that treatment with 100 mM
and 1 mM GlcN enhanced aggrecan and sulfated proteogly-
cans levels, while 10 mM GlcN treatment was inhibitory
[Fig. 5(C)]. Taken together, these results suggest that expo-
sure of OA chondrocytes to GlcN concentrations within the
range achieved physiologically with oral dosing of GlcN,
enhanced aggrecan gene expression and overcame the ef-
fect of prior treatment with IL-1b, while high doses of GlcN
were deleterious to the chondrocyte phenotype.
GLCN SUPPRESSES IL-1b-INDUCED MMP-13 EXPRESSION IN
BOTH OA CHONDROCYTE AND hMSCs PELLET CULTURES
We next tested the effect of GlcN on IL-1b-mediated
expression of downstream effectors of cartilage degradation,
Fig. 3. Effect of GlcN treatment on sGAG content in hMSCs under-
going chondrogenesis. Day 21 pellet cultures grown in the pres-
ence of DEX and TGF-b and treated with the indicated amount of
GlcN were digested with papain overnight, and sGAG content
was determined spectrophotometrically in cleared total cell lysates
using a Blyscan assay; with chondroitin 4-sulfate as a standard,
and was normalized to total protein content. Results show that
100 mM GlcN signiﬁcantly (P 0.001) enhanced sGAG levels,
while treatment with 10 mM GlcN was inhibitory (P 0.05) to the
accumulation of sGAG in hMSCs undergoing chondrogenesis.
The data represent the meanSD (*P 0.05), as determined by
ANOVA, of two independent experiments performed in triplicate.
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grown for 3e11 days as a monolayer or pellet culture in serum-containing medium supplemented with ascorbate and treated in the presence
or absence of 10 mM GlcN. (A) RT-PCR. Results show that GlcN blocks the time-dependent downregulation of aggrecan in both monolayer
and pellet cultures and enhanced collagen II expression in pellet cultures only. (B) Immunohistochemistry and alcian blue staining. Chondro-
cyte monolayer culture (day 7) and sections of pellet culture (day 11) were immunostained for collagen II or directly stained with alcian blue.
Results show that GlcN enhanced alcian blue staining in monolayer culture and increased collagen II levels in pellet culture.such as MMP-13, in pellet cultures of chondrocytes and
hMSCs. Normal and OA chondrocytes were grown in de-
ﬁned medium, treated with or without 5 ng/ml IL-1b for 24 h
on day 1, and then exposed to GlcN for one additional day
or 10 days. hMSCs undergoing chondrogenesis were
treated on day 11 with IL-1b for 24 h, and the cultures main-
tained for additional 10 days, up to day 21, in the presence or
absence of varying doses of GlcN. RT-PCR analysis showed
that both OA chondrocytes and MSCs expressed MMP-13,
particularly the former, and that treatment with IL-1b en-
hanced their basal levels of MMP-13. On the other hand,
IL-1b treatment induced a strong expression of MMP-13 in
normal chondrocytes, which originally did not express any
MMP-13 [Fig. 6(A)]. Following 10 mM GlcN treatment, this
upregulation of MMP-13 expression was completely blocked
in normal chondrocytes and partially reversed in OA chon-
drocytes and hMSCs [Fig. 6(A)]. In hMSCs, quantitative
RT-PCR analysis showed that following IL-1b exposure,
treatment with 100 mM GlcN inhibited MMP-13 expression
by two-fold, which was however upregulated by a 10 mM
dose of GlcN. In contrast, in OA chondrocytes, GlcN treat-
ment inhibited MMP-13 expression in a dose-dependent
manner [Fig. 6(B)]. Western blot analysis of proteins ex-
tracted from OA chondrocytes treated with IL-1b showed
that subsequent GlcN treatment reduced latent and active
MMP-13 protein levels in a dose-dependent manner
[Fig. 6(C)]. Taken together, these results suggest that GlcN
blocks the effects of pro-inﬂammatory mediators on both
chondrocytes and hMSCs undergoing chondrogenesis, byreducing the expression of matrix degrading enzymes,
such as MMP-13, thereby preventing cartilage matrix
damage.
Discussion
While GlcN salts have been considered a new class of
drugs with putative chondroprotective activity, their mecha-
nism of action is still not well understood and their beneﬁt is
still controversial, due in part to the small sample size and
short-term follow-ups of clinical studies11e13,21,26. In this
study, we have analyzed the in vitro effects of GlcN on
mesenchymal chondrogenesis and on the action of the pro-
inﬂammatory cytokine, IL-1b on chondrocytes and a multipo-
tential hMSC cell line undergoing chondrogenesis. We have
selected to use D (þ) GlcN-HCl because it is the major cir-
culating GlcN form in vivo. The sulfated form of GlcN found
in dietary supplements is modiﬁed to GlcN-HCl upon inges-
tion. Our studies showed that low doses (100 mM, 1 mM) of
GlcN enhanced differentiation of a multipotential hMSC cell
line undergoing chondrogenesis, by upregulating expres-
sion of cartilage matrix markers. These cells were estab-
lished from trabecular bone and express the cell surface
antigens Stro-1, CD 73 and CD10527,28. These cells give
rise to a homogenous population of stable proliferating pro-
genitor cells which display an undifferentiated phenotype
demonstrated by the absence of expression of collagen II
or aggrecan, although some collagen I RNA can be detec-
ted22e24,29. To validate the observed effects on hMSCs in
652 A. Derfoul et al.: Glucosamine modulates chondrogenic phenotypeFig. 5. Effect of GlcN on cartilage matrix gene expression in human chondrocytes challenged with IL-1b. Human OA chondrocytes were grown
as pellet cultures in deﬁned medium, treated with IL-1b for 24 h, then washed and treated in the presence or absence of the indicated amounts
of GlcN for additional 10 days. (A) Quantitative RT-PCR. Results of speciﬁc gene expression (expressed as average copy number relative to
that of G3PDH) show that in the absence of GlcN treatment, IL-1b inhibits both aggrecan (top) and collagen II (bottom) gene expression. Treat-
ment with 100 mM and 1 mM GlcN signiﬁcantly (P 0.001) enhanced aggrecan gene expression and maintained collagen II expression post-
IL-1b treatment, while treatment with 10 GlcN was inhibitory (P 0.05). The data represent the meanSD, of ﬁve independent experiments
performed in triplicate. (B) Day 11 pellet cultures grown as in (A) were digested with papain overnight and sGAG content was determined.
Results show that post-IL-1b treatment, 100 mM GlcN signiﬁcantly (P 0.001) enhanced sGAG content while treatment with 10 mM GlcN
suppressed (P 0.05) sGAG accumulation. The data represent the meanSD (*P 0.05), as determined by ANOVA, of two independent
experiments performed in triplicate. (C) Immunohistochemistry. Pellet cultures of OA chondrocytes grown as described in (A) were ﬁxed
and sections were immunostained for aggrecan and collagen II or directly stained with alcian blue for sulfated proteoglycans. Collagen II
and aggrecan protein levels and alcian blue staining of sulfated proteoglycans were increased by 100 mM and 1 mM GlcN, and were unaf-
fected or inhibited by 10 mM GlcN, respectively.
653Osteoarthritis and Cartilage Vol. 15, No. 6Fig. 6. GlcN suppression of IL-1b-induced MMP-13 expression in chondrocytes and hMSCs. (A) RT-PCR. Normal and OA human chondro-
cytes were cultured in high-density pellet cultures in ITS medium, and hMSCs were induced to undergo chondrogenesis as described above,
and treated with 5 ng/ml IL-1b for 24 h at day 1 or day 11, respectively, followed by treatment for an additional 10 days in the presence or
absence of 10 mM GlcN. The data show that GlcN inhibited IL-1b-induced MMP-13 expression in both OA and normal chondrocytes as
well as in hMSCs undergoing chondrogenesis. (B). Quantitative RT-PCR. Results from OA chondrocytes show that treatment with GlcN at
all concentrations inhibited MMP-13 gene expression, while in hMSCs, suppression was seen at 100 mM GlcN, with increase seen at
10 mM GlcN. The data represent the meanSD (*P 0.05) of ﬁve independent experiments each performed in triplicate. (C) Western
blot. Cell extracts (50 mg protein) prepared from OA chondrocytes grown and treated as in (B) were analyzed by immunoblotting for MMP-
13. Results show that GlcN treatment downregulated basal active MMP-13 levels and inhibited IL-1b-induced MMP-13 expression. A b-actin
blotting was used as a control for equal protein loading (not shown).general, we have also examined the effect of GlcN on pri-
mary human bone marrow stromal cells. Based on quantita-
tive RT-PCR and sGAG analyses, we found that both
100 mM and 1 mM GlcN treatment enhanced the levels of
aggrecan mRNA and increased sGAG content (unpub-
lished observation). To our knowledge, this is the ﬁrst study
to examine the effects of GlcN on hMSCs; this chondro-
enhancing effect could contribute toward improving carti-
lage repair and homeostasis mediated by adult stem cells.
Physiological plasma GlcN concentrations in human
adults ingesting a typical dose of GlcN supplement of
1500 mg/day (20 mg/kg in a 75 kg subject), ranged from
150 mM to 300 mM25 and reached the 10 mM range after re-
peated doses30. Our results showed that maximal enhance-
ment of the chondrogenic phenotype by GlcN treatment
was achieved at 100 mM, while higher doses were in fact in-
hibitory to both MSCs and chondrocytes. Others have also
reported similar protective effects at physiological doses of
GlcN, and chondrocyte toxicity has been associated with
GlcN concentrations exceeding 10 mM in vitro18,25,31.
The pro-inﬂammatory cytokine, IL-1b, induces a large
cascade of events that leads to cartilage damage. In prelim-
inary studies, we have examined the effect of GlcN treat-
ment prior to IL-1b exposure in the presence or absence
of GlcN. We observed that GlcN pre-treatment did not block
the transient inhibitory effect of the 24-h IL-1b treatment,
on markers of chondrogenic phenotype. However, GlcN
pre-treatment is protective if the cells were allowed to
recover for 9 days in the presence or absence of GlcN(unpublished data). Our studies showed that treatment of
chondrocyte pellet cultures with GlcN at physiological
doses of 100 mM, post-IL-1b exposure, inhibits expression
of MMP-13. GlcN treatment was also able to reduce gene
expression levels of the aggrecanases MMP-3 and A disin-
tegrin and metalloproteinase with thrombospondin motif-5
(ADAMTS-5), in both chondrocytes and MSCs (unpublished
data) suggesting that the protective effects of GlcN may be
mediated in part through downregulation of degrading en-
zymes that target both collagen II and aggrecan, two major
components of the cartilage matrix. Other studies have
shown that GlcN blocks other catabolic events such as IL-
1b-induced nuclear factor k beta (NFkB) activation, NO pro-
duction, and cyclooxygenase 2 (Cox-2) expression18,32.
These effects may account for our observation of the
GlcN effect on the maintenance of the differentiated pheno-
type of chondrocytes, grown in vitro in the presence of
serum, which normally would gradually lose cartilage matrix
gene expression as a function of time.
Although low doses of GlcN lack toxicity and inhibition of
MMP-13 expression and cartilage degradation showed
dose dependence, higher doses of GlcN, e.g., 10 mM, are
inhibitory to hMSC chondrogenesis and phenotype mainte-
nance of chondrocytes grown in deﬁned medium condi-
tions. High doses of GlcN have been shown to impair
metabolic activity leading to cell death in bovine chondro-
cytes31. In contrast, high doses of N-acetyl GlcN did not
induce chondrocyte cell death in vitro, and intra-articular in-
jection of N-acetyl GlcN in rabbit with experimental OA was
654 A. Derfoul et al.: Glucosamine modulates chondrogenic phenotypeshown to have chondroprotective and anti-inﬂammatory
activity17,33. Similar protection against pain was reported
in a recent trial of human OA, with a GlcN/chondroitin
combination16.
In addition to its chondroprotective effect, our studies
showed that treatment of chondrocyte pellet cultures with
GlcN at physiological doses of 100 mM, post-IL-1b expo-
sure, stimulates aggrecan expression and maintains colla-
gen II expression. Others have also shown GlcN to
induce proteoglycan synthesis and enhance sulfate incor-
poration. In an animal study, GlcN treatment was shown
to result in a signiﬁcant increase in sGAG content, without
change in collagen levels, in damaged knee joints of rabbits
injected with chymopapain, whereas no effect of GlcN on
sGAG content in normal cartilage was found34. In vitro,
GlcN treatment of human OA chondrocytes treated with
retinoic acid, IL-1b or grown in suspension under constant
agitation, enhanced aggrecan protein levels without any
effect on collagens18,35e37. Taken together, these results
suggest that GlcN may act by controlling inﬂammatory me-
diators and stimulating proteoglycan synthesis in response
to cartilage damage. Our ﬁndings are thus, in general
agreement with these published observations.
In conclusion, our data suggest that GlcN enhances
the chondrogenic phenotype of hMSCs by upregulating
expression of aggrecan and collagen II. In addition, GlcN pro-
motes the maintenance of the chondrocyte phenotype by
enhancing sulfated proteoglycan accumulation, and reduces
cartilage matrix degradation by inhibiting IL-b-induced MMP-
13 expression. Enhancing hMSC chondrogenesis in combi-
nation with blocking cartilage degradation may contribute
toward the chondroprotective properties of GlcN observed
in many studies. Understanding the mechanism of action of
GlcN on the differentiation of chondroprogenitor cells and
the activities of chondrocytes should provide a rational basis
for the development of chondroprotective therapies for
degenerative joint diseases.
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